04/01/2026
Let’s start here:
This is not anti-medicine.
This is about incentives.
Modern pharmaceutical systems are built on patents, scalability, and shareholder return. That shapes what gets studied, funded, and promoted.
And when you understand incentives, you understand outcomes.
Many medications originated from plants.
Aspirin from willow bark.
Digoxin from foxglove.
Paclitaxel from the Pacific yew tree.
The plant cannot be patented.
An isolated, modified molecule can.
That difference changes everything.
It determines where billions of dollars in research go.
It determines what is marketed.
It determines what becomes “standard of care.”
If an herb is studied using unrealistic dosages, extracted in ways not traditionally used, or tested in models that don’t reflect human use, the results can mislead.
Funding follows profit.
Herbs cannot be patented in their whole form.
So large-scale pharmaceutical funding rarely follows them.
Lack of funding does not automatically equal lack of value.
The word “alternative” did not appear randomly.
When herbal and community-based medicine began competing with institutional medicine in the early 20th century, language shifted. What had been common practice for centuries became labeled “alternative.”
Language shapes perception.
When corporations profit from the medication, the pharmacy distribution, the insurance relationships, and sometimes the treatment of side effects, incentives align around maintenance, not necessarily resolution.
That does not mean medication is useless.
It means you should understand the ecosystem you are participating in.
You can respect modern medicine and still ask better questions.
You can value pharmaceuticals and still value plants.
Wisdom is not either/or.
